Jan. 6, 2005 — Caliper Life Sciences Inc. and Predicant Biosciences Inc. today announced they have entered into an agreement under which Predicant has non-exclusively licensed a major portion of Caliper’s microfluidics patent estate for use with Predicant’s technology for the analysis of proteins using mass spectrometry.
Predicant is using microfluidics as a core technology for the company’s proteomic tests, which are designed to identify complex protein patterns in blood in order to diagnose and monitor disease. The agreement covers all of Caliper’s IP that is relevant to Predicant’s product development efforts. Financial details were not disclosed.
Caliper’s CEO, Kevin Hrusovsky, said in a prepared statement that the company has recently adopted a more open intellectual property out-licensing strategy, with the goal of permeating the life sciences, diagnostics and other industries with its microfluidics technologies.